PGEN Stock Analysis: Buy, Sell, or Hold?
PGEN - Precigen, Inc. Common Stock
$4.76
0.26 (5.90%)
▲
5d:
+0.11%
30d:
+13.76%
90d:
+17.41%
HOLD
MODERATE Confidence
Last Updated: February 2, 2026
Earnings: Mar 18, 2026
Smart Money Accumulation
PGEN is down 5.7% this week, but smart money is accumulating calls. Top strike: $5 2026-04-17 with 2,027 OI. Call ratio: 100% View Scanner →
Strength: 7.8/10
Get Alerted When PGEN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: PGEN shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: PGEN shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: PGEN is currently trading at $4.75, which is considered extended relative to its 30-day fair value range of $4.23 to $4.68.
Technical Outlook: Technically, PGEN is in a strong uptrend. Immediate support is located at $4.20, while resistance sits at $5.10. The stock is showing strong short-term momentum, up 5.9% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $8.25 (+83.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, PGEN is in a strong uptrend. Immediate support is located at $4.20, while resistance sits at $5.10. The stock is showing strong short-term momentum, up 5.9% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $8.25 (+83.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Fair Price Range
$4.23 -
$4.68
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
56.3%
All Signals
- BEARISH: Price extended above range
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+5.9%)
- BULLISH: Trading 83.7% below Wall St target ($8.25)
Fair Price Analysis
30-Day Fair Range
$4.23 -
$4.68
Current vs Fair Value
EXTENDED
Support & Resistance Levels
Support Level
$4.20
Resistance Level
$5.10
Current Trend
Strong Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
-31.22
Wall Street Target
$8.25
(+83.7%)
Revenue Growth (YoY)
19.4%
Last updated: February 02, 2026 3:08 PM ET
Data refreshes hourly during market hours. Next update: 4:08 PM
Data refreshes hourly during market hours. Next update: 4:08 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PGEN showing a specific setup today?
Insider Activity (6 Months)
6
Buys
5
Sells
+
Net
INSIDERS SELLING
Recent Transactions
Jeffrey B Kindler
SELL
106837 shares
2025-09-30
Randal J Kirk
SELL
1809667 shares
2025-09-30
Jeffrey B Kindler
SELL
67523 shares
2025-09-29
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 57 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1036 | 57 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$85 | 59 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$33 | 64 BUY |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
